Incident Use of Hydroxychloroquine for the Treatment of Rheumatoid Arthritis and Systemic Lupus Erythematosus During the COVID‐19 Pandemic

Incident Use of Hydroxychloroquine for the Treatment of Rheumatoid Arthritis and Systemic Lupus Erythematosus During the COVID‐19 Pandemic

Objective: We studied whether the use of hydroxychloroquine (HCQ) for COVID‐19 resulted in supply shortages for patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Methods: We used US claims data (IQVIA PHARMETRICS® Plus for Academics [PHARMETRICS]) and hospital electroni...

詳細記述

書誌詳細
主要な著者: Mercadé‐Besora, N, Guo, Y, Du, M, Li, X, Ramírez‐Anguita, JM, Moreno, A, Valente, A, Villalobos, F, Cheng, IL, Carrasco‐Ribelles, LA, van Swieten, MMH, Merkelbach, M, Magoya, M, Lasalvia, P, Pericàs‐Pulido, P, Berg, P, Bosco‐Lévy, P, Lillini, R, Ribeiro, R, Bagga, TK, Ramella, V, Khalid, S, Mayer, MA, Leis, A, Jödicke, AM, Burn, E, Prieto‐Alhambra, D, Català, M, Prats‐Uribe, A
フォーマット: Journal article
言語:English
出版事項: Wiley 2024

類似資料